Ren Xianying, Tahimic Candice Ginn T, Katoh Motonobu, Kurimasa Akihiro, Inoue Toshiaki, Oshimura Mitsuo
Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction,Tottori University, 86 Nishicho,Yonago, Tottori 683-8503, Japan.
Stem Cell Rev. 2006;2(1):43-50. doi: 10.1007/s12015-006-0008-9.
The recent emergence of stem cell-based tissue engineering has now opened up new venues for gene therapy. The task now is to develop safe and effective vectors that can deliver therapeutic genes into specific stem cell lines and maintain long-term regulated expression of these genes. Human artificial chromosomes (HACs) possess several characteristics that require gene therapy vectors, including a stable episomal maintenance, and the capacity for large gene inserts. HACs can also carry genomic loci with regulatory elements, thus allowing for the expression of transgenes in a genetic environment similar to the chromosome. Currently, HACs are constructed by a two prone approaches. Using a top-down strategy, HACs can be generated from fragmenting endogenous chromosomes. By a bottom-up strategy, HACs can be created de novo from cloned chromosomal components using chromosome engineering. This review describes the current advances in developing HACs, with the main focus on their applications and potential value in gene delivery, such as HAC-mediated gene expression in embryonic, adult stem cells, and transgenic animals.
近年来基于干细胞的组织工程学的出现,为基因治疗开辟了新途径。目前的任务是开发安全有效的载体,能够将治疗性基因导入特定的干细胞系,并维持这些基因的长期调控表达。人类人工染色体(HACs)具备基因治疗载体所需的几个特性,包括稳定的游离型维持以及大片段基因插入的能力。HACs还能携带带有调控元件的基因组位点,从而使转基因在类似于染色体的遗传环境中表达。目前,HACs通过两种方法构建。采用自上而下的策略,可通过切割内源性染色体来生成HACs。通过自下而上的策略,可利用染色体工程从克隆的染色体组件中从头创建HACs。本综述描述了开发HACs的当前进展,主要关注其在基因递送中的应用和潜在价值,例如HAC介导的基因在胚胎干细胞、成体干细胞和转基因动物中的表达。